Acquisition Pending

Angelini Pharma S.p.A. acquisition of Catalyst Pharmaceuticals

US$4.1bn equity value

Announced 7 May 2026 · NASDAQ: CPRX · US$31.50 cash per share

Advisers

Catalyst Pharmaceuticals

Target

Financial adviser
Legal adviser
Fairness opinion

Angelini Pharma S.p.A.

Acquirer

Financial adviser
Legal adviser
Gatti Pavesi Bianchi Ludovici (as Gatti, Pavesi, Bianchi, Ludovici Studio Legale)
Target
Catalyst Pharmaceuticals
Acquirer
Angelini Pharma S.p.A.
Target based in
United States
Buyer based in
Italy
Sector
Pharma
Tags
Pharma, Rare Disease

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.